Results 191 to 200 of about 11,605 (288)

Evolution of split-protein technologies in virology: From mechanistic discovery and diagnostics to therapeutic promise. [PDF]

J Virus Erad
Zhou K, Lei Y, Zhou Y, Zhan J.
europepmc   +1 more source

RNF138‐Mediated Ubiquitination and Degradation of NS5 Restricts Tick‐Borne Encephalitis Virus Infection

Advanced Science, EarlyView.
Host‐specific compatibility between RNF138‐like proteins and flavivirus NS5 determines NS5 stability. Mammalian RNF138 but not arthropod homologs recognizes and induces conserved NS5/RdRp K48‐linked ubiquitination and proteasomal degradation, thereby restricting viral replication. Ectopic RNF138 in mice attenuates TBEV‐induced pathogenesis. (Created in
Jialiang Sun, Weijing Yang, Hao Zhou, Shuai Li, Xin Jiang, Jianyang Gu, Wenyan Zhang   +6 more
wiley   +1 more source

Functional Characterization of Luciferase in a Brittle Star Indicates Parallel Evolution Influenced by Genomic Availability of Haloalkane Dehalogenase. [PDF]

Mol Biol Evol
Lau ES, Majerova M, Hensley NM, Mukherjee A, Vasina M, Pluskal D, Damborsky J, Prokop Z, Delroisse J, Bayaert WS, Parey E, Oliveri P, Marlétaz F, Marek M, Oakley TH.   +14 more
europepmc   +1 more source

Toward Nano‐Nutritional Medicine: A Remotely Activated Trans‐Vaccenic Acid‐Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy

Advanced Science, EarlyView.
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu, Yunlong Li, Hanmeng Liu, Peng Zhang, Mingjing Wang, Quanwei Sun, Wenshuo Yang, Zhengwei Song, Song Tan, Ye Yang, Peng She, Dengke Yin, Wei Shen   +12 more
wiley   +1 more source

Fungal infections in focus: accelerating non-invasive imaging from preclinical insights to clinical breakthroughs. [PDF]

Npj Imaging
Michiels L, Shameem M, Vanhoffelen E, Reséndiz-Sharpe A, Johnston SA, Beziere N, Vande Velde G.   +6 more
europepmc   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Enzyme miniaturization: Revolutionizing future biocatalysts. [PDF]

Biotechnol Adv
Ding N, Jiang Y, Lee S, Cheng Z, Ran X, Ding Y, Ge R, Zhang Y, Yang ZJ.   +8 more
europepmc   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

De novo luciferases enable multiplexed bioluminescence imaging. [PDF]

Chem
Yi-Hsuan Chen J, Shi Q, Peng X, de Dieu Habimana J, Wang J, Sobolewski W, Hsien-Wei Yeh A.   +6 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source